Objective. Fanconi anemia (FA) is an autosomal-recessive cancer susceptibil
ity syndrome with seven complementation groups. Six of the FA genes have be
en cloned (corresponding to subtypes A, C, D2, E, F, and G) and the encoded
proteins interact in a common pathway. Patient-derived mutations in FA gen
es have been helpful in delineating functional domains of FA proteins, The
purpose of this work was to subtype FA patient-derived cell lines in our re
pository and to identify FA gene mutations.
Methods. We subtyped 62 FA patients as type A, G, C, or non-ACG by using a
combination of retroviral gene transfer and immunoblot analysis. Among thes
e FA patients, we identified six FA-G patients for further analysis, We use
d a strategy involving amplification of FANCG/XRCC9 exons and direct sequen
cing to identify novel FANCG mutations in cell lines derived from these FA-
G patients, We functionally analyzed FANCG mutant alleles by transducing th
e corresponding cDNAs into a known FA-G indicator cell line and scoring cor
rection of MMC sensitivity,
Results. Our results demonstrate a wide range of mutations in the FANCG gen
e (splice, nonsense, and missense mutations), Based on this mutational scre
en, a carboxy terminal functional domain of the FANCG protein appears to be
required for complementation of FA-G cells and for normal assembly of the
FANCA/FANCG/FANCC protein complex.
Conclusion. The identification of patient-derived mutant alleles of FA gene
s can provide important insights to the function of FA proteins. FA subtypi
ng is also a necessary precondition for gene therapy. (C) 2001 Internationa
l Society for Experimental Hematology. Published by Elsevier Science Inc.